Guidance for the procurement of COVID‐19 convalescent plasma: differences between high‐ and low‐middle‐income countries
Vox Sanguinis2020Vol. 116(1), pp. 18–35
Citations Over TimeTop 10% of 2020 papers
Evan M. Bloch, Ruchika Goel, Silvano Wendel, Thierry Burnouf, Arwa Z. Al‐Riyami, Ai Leen Ang, Vincenzo De Angelis, Larry J. Dumont, Kevin J. Land, Cheuk‐Kwong Lee, Adaeze Oreh, Gopal Kumar Patidar, Steven L. Spitalnik, Marion Vermeulen, Salwa Hindawi, Karin van den Berg, Pierre Tiberghien, Hans Vrielink, Pampee P. Young, Dana V. Devine, Cynthia So‐Osman
Abstract
There has been wide-scale adoption of CCP in many HICs, which could increase if clinical trials show efficacy of use. By contrast, LMICs, having received little attention, require locally applicable strategies for adoption of CCP.
Related Papers
- → Chilblain‐like lesions after BNT162b2 mRNA COVID‐19 vaccine: a case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS‐CoV‐2(2021)26 cited
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → ОПЫТ ИССЛЕДОВАНИЯ СЕРОПРЕВАЛЕНТНОСТИ К ВИРУСУ SARS-CoV-2 НАСЕЛЕНИЯ ИРКУТСКОЙ ОБЛАСТИ В ПЕРИОД ВСПЫШКИ COVID-19(2020)2 cited
- → Особенности сахароснижающей фармакотерапии у пациентов с SARS-CoV-2 (COVID-19)(2021)